EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results